Advertisement

Topics

Biogen and Sobi Company Profile

19:42 EDT 19th October 2017 | BioPortfolio

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.


News Articles [302 Associated News Articles listed on BioPortfolio]

Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & ...

BiogenMatt Fearer, +1-781-464-3260public.affairs@biogen.comorBenjamin Strain, +1-781-464-2442IR@biogen.com Read more...

Head to Head Survey: Biogen (BIIB) and Its Peers

Biogen is one of 45 public companies in the "Biopharmaceuticals" industry, but how does it contrast to its peers? We will compare Biogen to similar companies based on the strength of its analyst recom...

Sobi drug gains NICE approval after 4 year wait

Sobi’s Xiapex, a treatment for a condition causing contraction of the hand and fingers, has finally been recommended by NICE after a four-year battle to get it funded by the NHS. NICE originally ...

Sobi's Niche Distribution Platform No Longer For Sale

Sobi's new CEO Guido Oelkers has decided the company's Partner Products business is to remain an integral part of its...   

Biogen up on new Spinraza data

US biotech major Biogen saw its shares rise 4.03% to $327.62 by mid-morning today, after the company…

Analyzing Biogen

Biogen and Cardiome Pharma Corporation are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, anal...

FDA Grants Orphan Drug Designation to Sobi’s Treatment for MPS IIIA

STOCKHOLM–(BUSINESS WIRE)–Swedish Orphan Biovitrum AB (publ) (Sobi™) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the company’s de...

Biogen-Aktie: Chance/Risiko-Profil wird besser! - Aktienanalyse

Zürich - Biogen-Aktienanalyse von Analyst Carter Gould von der UBS: Laut einer Aktienanalyse vertritt der Analyst Carter Gould von der UBS im Hinblick auf die Aktien des US-Biotechkonzerns Biogen I.....

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

PubMed Articles [5 Associated PubMed Articles listed on BioPortfolio]

Biogen pays Forward in Tecfidera dispute.

A new method for quantifying the performance of EEG blind source separation algorithms by referencing a simultaneously recorded ECoG signal.

Blind source separation (BSS) algorithms extract neural signals from electroencephalography (EEG) data. However, it is difficult to quantify source separation performance because there is no criterion...

Leveraging a CHO cell line toolkit to accelerate biotherapeutics into the clinic.

The Biogen upstream platform is capable of delivering equivalent quality material throughout the cell line generation process. This allows us to rapidly deliver high quality biopharmaceuticals to pati...

On the effects of multimodal information integration in multitasking.

There have recently been considerable advances in our understanding of the neuronal mechanisms underlying multitasking, but the role of multimodal integration for this faculty has remained rather uncl...

The Temporal Dynamics of Response Inhibition and their Modulation by Cognitive Control.

Behavioral adjustments require interactions between distinct modes of cognitive control and response inhibition. Hypothetically, fast and global inhibition is exerted in the reactive control mode, whe...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive

To determine the maximal safe daily dose of BG8962 (rCD4) which can be administered by continuous subcutaneous infusion (CSCI) over 24 hours; to determine the pharmacokinetics of BG8962 wh...

Safety and Tolerability of Repeat Courses of IM Alefacept

Previous Biogen studies have provided experience with the tolerability, immunogenicity, and efficacy of a single and multiple 12-week courses of therapy of alefacept. At this stage, experi...

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change cert...

Pregnancy Exposure Registry for AVONEX

This is an observational, exposure-registration and follow-up study, which will be conducted in the United States (US). The AVONEX® Pregnancy Exposure Registry is designed to monitor pre...

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy

Study phase: Phase II Investigational product, dosage, and route of administration: Ibritumomab tiuxetan ("Zevalin) is composed of a murine IgG1 monoclonal antibody (ibritumomab) covalentl...

Companies [31 Associated Companies listed on BioPortfolio]

Biogen and Sobi

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare ...

Swedish Orphan Biovitrum AB

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families. Sobi have a diversi...

Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the li...

Biogen Idec Inc.

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Idec and Elan Corporation, plc

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

More Information about "Biogen and Sobi" on BioPortfolio

We have published hundreds of Biogen and Sobi news stories on BioPortfolio along with dozens of Biogen and Sobi Clinical Trials and PubMed Articles about Biogen and Sobi for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biogen and Sobi Companies in our database. You can also find out about relevant Biogen and Sobi Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record